rs786204481
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000642.3(AGL):c.2309-1G>A variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000018 in 1,610,292 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000642.3 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Publications
- glycogen storage disease IIIInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Ambry Genetics, Laboratory for Molecular Medicine, Myriad Women’s Health, Orphanet, G2P, PanelApp Australia, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| AGL | NM_000642.3 | c.2309-1G>A | splice_acceptor_variant, intron_variant | Intron 17 of 33 | ENST00000361915.8 | NP_000633.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 152050Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000800 AC: 2AN: 250122 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.0000192 AC: 28AN: 1458242Hom.: 0 Cov.: 31 AF XY: 0.0000248 AC XY: 18AN XY: 725492 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000658 AC: 1AN: 152050Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74250 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Glycogen storage disease type III Pathogenic:4
- -
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
- -
This sequence change affects an acceptor splice site in intron 17 of the AGL gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in AGL are known to be pathogenic (PMID: 19299494). This variant is present in population databases (rs786204481, gnomAD 0.002%). Disruption of this splice site has been observed in individuals with glycogen storage disease III (PMID: 20648714, 27460348, 34820282). ClinVar contains an entry for this variant (Variation ID: 188804). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Glycogen storage disease IIIa Pathogenic:1
Variant summary: The c.2309-1G>A (aka IVS17-1G>A) in a AGL gene is a splice-site variant that alters a highly conserved nucleotide. 5/5 in silico tools via Alamut predict this variant to disrupt a canonical acceptor sequence, however these predictions have yet to be confirmed by functional assay. The variant is absent from control dataset of ExAC (~120120 chrs tested), but is present at a low frequency in gnomAD dataset (2/245384 chrs tested). The observed frequency does not exceed the maximum expected allele frequency for a pathogenic variant of 0.00228. The variant has been reported in affected individuals with enzymatically confirmed dx of GSDIII via publications and is cited as Likely Pathogenic by a reputable database/clinical laboratory. Taken together, the variant was classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at